<DOC>
	<DOCNO>NCT00979589</DOCNO>
	<brief_summary>The purpose study assess effect 3-month regimen clopidogrel initiate load dose ( LD ) 300 mg follow 75 mg/day first 21days versus 3-month regimen ASA 75 mg/day alone reduce 3-month risk stroke ( ischemic hemorrhagic , primary outcome ) initiate within 24 hour symptom onset high-risk patient TIA minor stroke .</brief_summary>
	<brief_title>Clopidogrel High-risk Patients With Acute Non-disabling Cerebrovascular Events</brief_title>
	<detailed_description>Inclusion criterion : 1 . Adult subject ( male female ≥ 40 year ) 2 . Acute non-disabling ischemic stroke ( NIHSS≤3 time randomization ) treat study drug within 24 hour symptoms onset . Symptom onset define `` last see normal '' principle . 3 . TIA ( Neurological deficit attribute focal brain ischemia , resolution deficit within 24 hour symptom onset ) , treat study drug within 24 hour symptoms onset moderate-to-high risk stroke recurrence ( ABCD2 score ≥ 4 time randomization ) . Symptom onset define `` last see normal '' principle . 4 . Informed consent sign Primary Efficacy Endpoint : Percentage patient 3-month new vascular event , define event follow : Any stroke ( ischemic hemorrhage ) .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Inclusion criterion : Adult subject ( male female≥40 year ) Acute nondisabling ischemic stroke ( NIHSS≤3 time randomization ) treat study drug within 24 hour symptoms onset . Symptom onset define `` last see normal '' principle TIA ( Neurological deficit attribute focal brain ischemia , resolution deficit within 24 hour symptom onset ) , treat study drug within 24 hour symptom onset moderatetohigh risk stroke recurrence ( ABCD2 score≥4 time randomization ) .Symptom onset define `` last see normal '' principle Informed consent sign Diagnosis hemorrhage pathology , vascular malformation , tumor , abscess major nonischemic brain disease ( e.g. , multiple sclerosis ) baseline head CT MRI Isolated pure sensory symptom ( e.g. , numbness ) , isolate visual change , isolate dizziness/vertigo without evidence acute infarction baseline head CT MRI Modified Rankin Scale Score &gt; 2 randomization ( premorbid historical assessment ) NIH Stroke Score≥4 randomization Clear indication anticoagulation ( presumed cardiac source embolus , e.g. , atrial fibrillation , prosthetic cardiac valve know suspected endocarditis ) Contraindication clopidogrel ASA Known allergy Severe renal hepatic insufficiency Severe cardiac failure , asthma Hemostatic disorder systemic bleeding History hemostatic disorder systemic bleeding History thrombocytopenia neutropenia History druginduced hematologic hepatic abnormality Low white blood cell ( &lt; 2 x109/l ) platelet count ( &lt; 100 x109/l ) Use thrombolysis within 24 hour prior randomization History intracranial hemorrhage Anticipated requirement longterm nonstudy antiplatelet drug , NSAIDs affect platelet function Current treatment ( last dose give within 10 day randomization ) heparin therapy oral anti coagulation Gastrointestinal bleed major surgery within 3 month Planned likely revascularization ( angioplasty vascular surgery ) within next 3 month ( clinically indicate , vascular imaging perform prior randomization whenever possible ) Scheduled surgery interventional treatment require study drug cessation Qualifying TIA minor stroke induce angiography surgery Severe noncardiovascular comorbidity life expectancy &lt; 3 month Women childbearing age practice reliable contraception document negative pregnancy test Currently receive investigational drug device</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stroke</keyword>
	<keyword>transient ischemic attack</keyword>
	<keyword>acute treatment</keyword>
	<keyword>acute non-disabling cerebrovascular event</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>clopidogrel combine ASA</keyword>
	<keyword>recurrence stroke vascular event</keyword>
</DOC>